Recent studies suggest that putative regulatory lymphocytes can effect antigen-specific down-regulation of autoimmunity. But we have yet to see how much this improves our picture of autoimmune disease progression.
The regulation of autoreactive T cells may in some respects be modeled on the behaviour of the lac operon of Escherichia coli, the essential paradigm for differential gene regulation [1] . De-repression of the lac operon relies on encounter with the primary target, lactose. But if other factors -notably high glucose concentrationkeep or render cellular cyclic AMP levels low, the catabolite activator protein that is required for maximal transcription from the lac operon remains or becomes inactive, and the de-repression of the operon is largely ineffective, irrespective of lactose concentration. Likewise, although full activation of autoreactive lymphocytes relies on encounter with the primary target, which is self antigen, other factors that are operative at the time of, or subsequent to, antigen exposure can conspire to reduce or re-direct the lymphocytes' activity.
Given the potential therapeutic importance for people with autoimmune diseases, what these regulatory 'other factors' might be is a subject of intense interest. Recent studies of rodent experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central nervous system that is reminiscent of human multiple sclerosis, indicate anew that the mystery factors may include 'regulatory' lymphocytes. These findings offer an attractive hypothesis, suggesting that it might be possible to down-regulate autoimmune disease antigen-specifically, rather than through global immunosuppression.
The deletion of autoreactive T cells during development of the thymus is not universal [2] . Such cells can enter the peripheral immune system, but in most cases they remain unactivated because there is no contact with self antigens. However, injecting healthy rodents with complete Freund's adjuvant containing either myelin basic protein (MBP) or an MBP peptide can activate self-MBP-reactive peripheral T cells. On activation, peripheral MBP-reactive T cells express on their surfaces the integrins LFA-1 and VLA-4, which help them to cross the endothelial lining of blood vessels and so get into tissues [3] . If the T cells' antigenic target is expressed in a tissue that they enter -for example, MBP is expressed in the central nervous system -the T cells may proliferate in situ and elicit autoimmune disease. Thus, injection of MBP can induce EAE in rodents (Fig. 1) . Activated T cells from rodents with MBP-induced EAE can transfer the disease to recipient animals. In this way, the 'culprit' class of T cells in EAE were shown usually to be CD4-bearing cells, reactive to an MBP peptide presented by specific class II alleles of the major histocompatibility complex (MHC). The suggestion that CD4+ T cells are involved in EAE, as well as in other autoimmune diseases such as type I diabetes, is consistent with the observed linkage of disease penetrance to several class II MHC alleles.
CD4
+ T cells fall into at least two categories, Thl and Th2. Activated Thl cells produce interleukin (IL)-2, interferon y, and transforming growth factor (TGF)-oa or -1; the combined action of these factors elicits inflammation. Activated Th2 cells, by contrast, secrete IL-4, which helps B cells to produce high-affinity antibodies of certain isotypes, such as IgGl or IgE in mice. CD4 + T cells can be biased towards a Thl fate if they are primed by macrophages in the presence of IL-12, whereas priming by B cells biases them towards the Th2 fate. The resulting commitment of a T-cell clone to becoming Thl or Th2 seems relatively stable, both in vitro and in vivo. Thus, cloned MBP-reactive Thl cells transfer disease, whereas cloned MBP-reactive Th2 cells cannot [3] . A Thl inflammatory response mounted in the central nervous system elicits extensive cellular infiltration, leading to loss of electrophysiological axonal integrity, and to the animal's paralysis.
But other factors can counteract the pathogenic effects of MBP-reactive Thl cells: in certain inbred strains of rodents, MBP-induced EAE goes into spontaneous remission. As MBP is abundant in the central nervous system, this remission cannot be easily attributed to the primary target of the Thl cells becoming limiting. So, what are the other factors that suppress or re-direct the inflammatory response? To date, the simplest system for studying EAE uses mice transgenic for T-cell receptor (TCR) genes taken from MBP-reactive encephalitogenic Thl T-cell clones. In these mice, the inheritance of prerearranged TCR transgenes largely precludes rearrangement of the endogenous TCR genes, so that almost all the T cells in these mice express the TCR characteristic of the MBP-reactive T-cell clone.
Goverman et al. [4] reported that such mice are more likely to develop EAE in response to injection of MBP, a result which is to be expected given that the transgenic mice house a greatly increased frequency of precursor T cells reactive toward MBP. In addition, a fraction of the transgenic mice developed EAE spontaneously when they were kept in non-sterile conditions. The authors [4] considered that instead of being triggered by MBP, the T cells in these spontaneous EAE mice could have been activated polyclonally, for example by bacterial superantigens [5] . About 14 % of animals in an analogous set of mice also developed EAE spontaneously, but in this case the disease arose even though the mice were kept in 'specific-pathogen-free' conditions [6] . However, as the 'specific pathogens' that are routinely excluded in such conditions were historically defined in relation to immunocompetent mice, the transgenic mice may have been positive for (and primed by) other organisms that are not pathogenic for normal mice.
Alternatively, extravasation of virgin T cells into tissues, which is usually assumed not to occur at all, may in fact occur very occasionally: an extravasation rate of, say, 1 in 106 cells could permit about 100 virgin T cells to enter tissues at any one time from a steady state peripheral immune system containing perhaps 108 such cells. Such extravasation might result from occasional spontaneous expression of integrins, such as VLA4, which at such a low frequency would be undetectable by any known method for analysing cell-surface proteins in lymphocyte populations. Occasional extravasation of virgin cells might be a mechanism for routine irfmune surveillance, and possibly for the developmental homing of epithelial lymphocytes. Ordinarily, there would be no consequences of extravasation, as the chances are slim that T cells entering a tissue would recognise self antigens therein. But if, as in the TCR-transgenic mice, the frequency of precursor T cells reactive toward the tissue is greatly exaggerated, an autoreactive immune response could ensue in response to even a low level of presented antigen.
Whatever the mechanism of 'spontaneous' priming in the two sets of transgenic mice, the Thl phenotype is in both cases preserved. Because allelic exclusion means that both sets of transgenic mice have no other class of oa3-TCR-bearing T cell, the results show that the only oat-T cells required to initiate or maintain EAE are CD4+ Thl cells. This point is taken one stage further by Lafaille et al. [6] , who crossed their TCR-transgenic mice with mice congenitally lacking the recombinase activating gene, RAG1. Because RAG1-/ -mice cannot undertake immunoglobulin-type gene rearrangement, they contain no B cells or T cells. But the transgenically driven MBP-reactive CD4+ T cells can develop, because their TCR is encoded by pre-rearranged transgenes. The finding that these mice, too, develop EAE shows that no other lymphocyte is required for disease development. Interestingly, the incidence of spontaneous EAE in these mice is 100 %, with no remission occurring. In other words, 'other factors' ameliorating disease are missing from the immunodeficient, 'B-cell-less, T-cell-less' RAG -/-mice, suggesting that the missing factors include B or T lymphocytes.
A high incidence of autoimmune diseases in people with immunodeficiencies, and in their relatives, was reported over thirty years ago [7] . Thus, immunodeficiency may itself be the problem that leads to autoimmune disease. Infections that are not cleared may elicit chronic priming of lymphocytes. Recent studies by Cyster et al. [8] indicate that, in immunocompetent animals, autoreactive lymphocytes may be unable to initiate autoimmune responses because of competition from the full immune repertoire for limited anatomical sites of activation. In immunodeficient animals, by contrast, these sites would be 'open'. Thus, RAG1 -/ -, TCR-transgenic mice may be more prone to disease because they are more immunodeficient, and so may prime the transgenic T cells more readily. Alternatively, it might be the case, as it was thought to be thirty years ago, that immunodeficiency deprives an animal of regulatory lymphocytes that keep autoreactive effector lymphocytes in check.
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The obvious difference between the RAG1 + /+ , MBP-TCR transgenic mice and their RAG 1 -/ -counterparts is the presence in the former of B cells. In an MBP immunization of rats undertaken by Day et al. [9] , priming of MBP-reactive T cells by B cells rather than macrophages was encouraged by co-administration of MBP peptide coupled to anti-IgD. Almost no development of EAE resulted. The authors considered that this was because MBP presentation by B cells skewed the CD4 + T-cell response towards Th2 and away from inflammatory tissue damage. Interestingly, the spleen cells from the 'immunized but protected' mice were able to transfer disease to secondary recipients. This might lead to questions about the current belief that the Thl and Th2 phenotypes are relatively stable: perhaps the protected mice retained uncommitted CD4 + T cells that were primed to Thl activity in the secondary recipient.
Given this precedent, Lafaille et al. [6] hypothesize that priming by MBP-reactive B cells shifts the balance in some of the RAG1 + / + , TCR-transgenic mice towards a non-pathogenic Th2 response. Certainly the healthy RAG1'/+, TCR-transgenic mice showed little lymphocytic infiltration of the central nervous system. But how, in the absence of antigen in the periphery, would rare MBP-reactive B cells in a polyclonal repertoire prime the transgenic T cells sufficiently early to affect the Thl:Th2 balance? The answer isn't obvious, but in such a simplified system the hypothesis can be tested, for example by restoring B cells to the RAG1 -/ -transgenic mice, or by crossing the TCR transgene into a purely T-cell-deficient genetic background.
Two other approaches have recently been taken in the search for regulatory lymphocytes in EAE. In the first, Sercarz and colleagues [10] isolated CD4 + T. cells that are reactive to a peptide of the TCR of the predominant anti-MBP encephalitogenic T cells, from mice with a B1O.PL genetic background recovering from MBPinduced EAE. Injection of such TCR-reactive cells into B1O.PL mice, 24 hours before injection of MBP, largely prevented EAE, strongly suggesting that the TCR-reactive cells arising in mice undergoing remission are natural and specific down-regulators of pathogenic MBP-reactive T cells. Perhaps surprisingly, however, the. reactive T-cell clones did not seem to affect other T cells expressing exactly the same TCR variable region and hence bearing the same epitope as the encephalitogenic clones [10] .
In a second approach, Chen et al. [11] isolated CD4 + , MBP-reactive T cells from mice with an SJL genetic background that were fed low doses of MBP. The idea of feeding the mice MBP is based on the observation that we display tolerance to foreign proteins when we encounter them as food. The result is that mice fed MBP do not develop disease but instead gain oral tolerance toward MBP, and this strategy is now being applied to humans with multiple sclerosis [12] . The T-cell clones that Chen et al. [11] isolated from the 'orally tolerized' animals were able to suppress development of EAE in recipient mice that were co-injected with MBP. Interestingly, the T-cell clone's TCR usage was identical to that of an encephalitogenic T-cell clone; the cells, called 'Th3 cells' by Chen et al. [11] , differed only in the secretion of an unusual cytokine mixture of IL-4, IL-10, and TGF-3. These data suggest that a single T-cell clone, induced by distinct physiological mechanisms, can oppose the activation of a sister pathogenic effector cell type. As they use the same TCR as the encephalitogenic clones, why don't cells of the type seen by Chen et al. [11] develop in the TCR-transgenic mice, and thereby suppress disease? Certainly one might predict that the transgenic mice could be orally tolerized by the actions of such T-cell clones.
What can we conclude about human multiple sclerosis and other autoimmune diseases from these studies? Having T-cell precursor frequencies skewed towards recognizing self antigens can clearly be a problem, and any condition, either genetic or environmental, that encourages such a situation is a potential disease-predisposing condition. Thus, in the developed world, an increased incidence of autoimmunity might be related to a delayed and restricted exposure to pathogens and hence to a relatively exaggerated autoreactive T-cell population. We may also conclude that a single clone of autoreactive T cells can be a potent effector of disease, although in reality this is an unlikely scenario. In most cases, autoimmunity is chronic, the effector immune response targeting one self-antigen after another. Furthermore, recent studies have indicated that CD8 + T cells, as well as CD4 + T cells, are critically involved in a murine model of autoimmune diabetes [13, 14] .
We may also begin to conclude that during the evolution of the autoimmune response, lymphocytes arise which are specific for either self-antigen or the autoreactive T cells themselves, and which may oppose the action of the pathogenic effector cells. While good news for all of us, such cells have yet to be placed convincingly into a scenario of disease remission. Moreover, if such cells re-direct rather than abrogate an immune response, the good news may only be temporary. In autoimmune diabetes, the attack on the pancreas may be induced by Thl cells reactive to the enzyme glutamic acid decarboxylase (GAD), which is expressed in pancreatic islets and in a subset of neurons [15] . Re-direction of the inflammatory attack into a Th2 response may spare the pancreas, but it may elicit a second serious disease, stiff man syndrome, which is characterized by high-titre antibodies against neuronal GAD. Translating the new findings from rodent studies into safe therapeutic advances in the treatment of autoimmune disease may take some time yet.
